Amneal Pharmaceuticals releases abiraterone acetate tablets, USP, 250 mg and 500 mg following FDA approval of Amneal’s Abbreviated New Drug Application (ANDA), approved for its use in combination with prednisone. Abiraterone acetate tablets, USP, 250 mg, and 500 mg, are the generic version of Zytiga for the treatment of metastatic prostate cancer. Following approval of the additional 500 mg strength, Amneal has increased commercialization to increase access.

Amneal Pharmaceuticals, Inc